J&J Covid Vaccine New Data Is Out

J&J Covid Vaccine New Data Is Out

Not too long ago, we were revealing that J&J covid vaccine’s efficiency is just as high as the one that Pfizer and Moderna vaccines have. Check out the latest reports revealed by The New York Times. 

The NYT notes that even if the vaccine was once dismissed as less effective, now seems to be preventing infections and illness as well as the two mRNA options.

J&J vaccine against covid is efficient 

It’s been recently revealed that roughly 17 million Americans received the Johnson & Johnson Covid vaccine, only to be told later that it was the least protective of the options available in the United States.

Now, it seems that the game is changing and new data suggest that the vaccine is now preventing infections, hospitalizations and deaths at least as well as the Pfizer-BioNTech and Moderna vaccines. Check out our previous article in order to learn more news about the issue. 

News about the J&J covid vaccine is out 

CNN now reveals that the US public and even some health experts may have underestimated the Covid-19 vaccine made by Janssen, a division of Johnson & Johnson, new data shows. More than that, it’s also important to note the fact that there is emerging evidence that it could still play an important role ahead.

A study published Thursday in the medical journal JAMA Network Open found that the J&J vaccine remains durable and effective, even though the surge of cases caused by the Delta variant.

“It was 76% effective overall in preventing Covid-19 infections and 81% effective in preventing Covid-related hospitalizations. The study also showed that it provided lasting immunity at least six months after the shots.”

Check out the study in the official notes in order to learn all that there’s is to know about the issue. 

“What we saw in the summertime and the fall during the Delta surge is that all three vaccines protected very, very well. But breakthrough rates in August, September of last year with the Janssen vaccine were slightly higher than Pfizer, and Moderna was slightly lower. But those differences were relatively small.”

This is what Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston said. He helped to develop and study the J&J vaccine.

Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.